Bristol-Myers Squibb is locked in some pretty big marketing battles—but it’ll have to soldier on without its commercial leader. On Monday, the New Jersey drugmaker said EVP and Chief Commercial ...
Bristol-Myers Squibb plans to spend more money on direct-to-consumer advertising for its immuno-oncology drug, Opdivo, company executives told investors during a first-quarter earnings call. BMS CFO ...
If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for the first-line treatment of untreated, unresectable or metastatic urothelial carcinoma in ...
Bristol Myers Squibb snagged an FDA go-ahead to open another front in Opdivo's rivalry with Merck & Co.'s Keytruda. The FDA approved the combination of Opdivo and Exelixis’ tyrosine kinase inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback